Potential Benefits: Significant Weight Loss: When combined with GLP-1 therapy, Cagrilintide has led to greater reductions in body weight than GLP-1s alone in clinical trials
Moving forward, it is important for clinicians to be aware of the possibility of known or novel injection-site reactions in response to GLP-1RAs
The absence of a documented association in clinical trials and post-marketing surveillance supports the view that any perceived link between Saxenda and UTIs is likely coincidental rather than causal
Microcrystalline cellulose is used as a filler to stabilize the tablets and ensure easy handling
Short-acting GLP-1RAs are administered before a meal, and have a greater effect on gastric emptying and postprandial glucose, primarily after the meal, whereas long-acting GLP-1RAs have less of an effect on gastric emptying and postprandial glucose excursions, but a more pronounced effect on fasting blood glucose and weight loss (140)
Dank seines einzigartigen Wirkmechanismus, seines Gewichtsverlustpotenzials und seines praktischen Dosierungsschemas ist es eine vielversprechende Option fr Diabetiker